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SINCE the first human liver transplanta-tion in Denver on March 1, 1963, numer-
ous refinements in surgical techniques and in 
perioperative care have been made, the mech-
anism of graft rejection has been more pre-
cisely understood, and safer and more effec-
tive immunosuppressive agents have been 
discovered. I . 3 Now, in 1987, it is well accepted 
that liver transplantation is often the only 
effective therapy for many advanced liver. 
diseases. 
We will report here, as a landmark of our 
continuing efforts, the survival of patients 
with various end-stage liver diseases after 
liver transplantation from our own experience 
in 1,000 hepatic homograft recipients under 
cyclosporine-steroid therapy. 
CASE MATERIALS AND METHODS 
Since the introduction of cyclosporine-steroid therapy 
for our liver recipients in March 1980, 1,000 patients 
received liver homografts for various end-stage liver dis-
eases by July 1987 at our institutes in Denver (in 1980), in 
Pittsburgh (since 1981), and Dallas (since 1985). 
Of the 1,000 liver recipients, 666 were adults of age 18 
years or older, and 334 were children of the ages younger 
than 18 years. The youngest liver recipient was 26 days 
old, and the oldest one was 76 years old at the time of 
transplantation. The numbers of patients in various age 
groups are listed in Table 1. 
The liver diseases of adult recipients and those of 
pediatric recipients are listed in Table 2 and Table 3. 
From the Department of Surgery. University Health 
Center of Pittsburgh. University of Pittsburgh. and the 
Veterans Administration Medical Center. Pittsburgh. 
Supported by research grants from the Veterans 
Administration and Project Grant No. AM 29961 from 
the National Institutes of Health. Bethesda, MD. 
Address reprint requests to Shunzaburo Iwatsuki. 
MD. Department of Surgery, 3601 Fifth Ave, Falk Clinic 
4 West, Pittsburgh. PA 15213. 
© 1988 by Grune & Stratton. Inc. 
0041-1345/88/2001-1178$03.00/0 
according to the incidence. Three most common liver 
diseases among adult recipients were (1) postnecrotic 
cirrhosis (including chronic active hepatitis and crypto-
genic cirrhosis), (2) primary biliary cirrhosis, and (3) 
primary sclerosing cholangitis. Those of pediatric recip-
ients were (1) 'biliary atresia (including extrahepatic and 
intrahepatic type, biliary hypoplasia and Alagille's syn-
drome), (2) liver-based inborn metabolic errors (alpha-
I-antitrypsin deficiency disease, Wilson's disease, tyro-
sinemia, and others), and (3) postnecrotic cirrhosis. 
The survival data were analyzed as of September 1, 
1987, using the method oJ Kaplan-Meier. The statistical 
comparisons were made by the methods of Breslow and of 
Mantel-Cox. The difference was considered as significant 
when the P value was less than .05. 
RESULTS 
Overall survival rates of the 1,000 recip-
ients treated with cyclosporine-steroid ther-
apy were three times higher than those of 170 
patients treated with azathioprine-steroids 
before 1980. One- to 5-year survival rates 
were 74%, 7]%, 67%, 65%, and 64%, respec-
tively, as shown in Fig 1. Five percent to 10% 
survival superiority of the pediatric recipients 
had existed for pediatric recipients during the 
azathioprine era before 1980. Since 1981, the 
survival rates of adult and of pediatric recip-
ients are identical under cyclosporine-steroid 
therapy (Figure 2). 
The survival rates of various age groups of 
recipients were compared in Table 1. The 
survival rates of children under the age of 1 
year and those of adults aged 60 years or older 
were significantly lower than overall survival 
rates of pediatric and adult recipients, respec-
tively. 
The survival rates were compared among 
three most common liver diseases of adult 
recipients (Fig 3) and among those of pediat-
ric recipients with different diseases (Fig 4). 
Survival rates of adult recipients who had 
postnecrotic or cryptogenic cirrhosis, those 
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Table 1. Number of Patients in Various Age Groups, and 1- to 5-Year Survival Rates 
Age (yr) No. Patients 1 year 
0-1 30 63 
1-2 40 66 
2-3 48 70 
3-4 35 71 
4-5 29 58 
5-10 84 78 
10-18 68 80 
18-30 128 77 
30-40 160 77 
40-50 209 75 
50-60 121 76 
60-70 47 59 
70 and older 100 
with primary biliary cirrhosis, and those of 
primary sclerosing cholangitis were nearly 
identical (Fig 3). In pediatric recipients, sur-
vival rates of children with biliary atresia, 
those of liver-based inborn metabolic errors, 
and those of post necrotic or cryptogenic cir-
rhosis were also similar (Fig 4). 
The influence of hepatitis B antigen 
(HBsAg) upon survival after liver transplan-
tation and the recurrence of hepatitis B in the 
graft liver were studied. Among 276 recipients 
Table 2. Liver Diseases of Adult Recipients 
Disease 
Cirrhosis (postnecrotic, cryptogen-
ic, alcoholic) 
Postnecrotic and cryptogenic 
H8.Ag positive 
Alcoholic 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
liver-based inborn metabolic errors 
(Alpha-1-antitrypsin deficiency, 
Wilson's, etc) 
Primary hepatic malignancy 
Fulminant hepatic failure 
Secondary biliary cirrhosis 
8udd-Chiari syndrome 
Bile duct cancer 
Secondary hepatic malignancy 
Others· 
No. Patients 
278 
237 
36 
41 
165 
74 
35 
33 
27 
13 
13 
10 
7 
11 
·Cystic fibrosis (3). adenomatosis (2). biliary atresia, 
cryptococcal cholangitis, congenital hepatic fibrosis, polycys-
tic disease, trauma, Iymphoangiomatosis. 
Actuarial Survival (%) 
2 years 3 years 4 years 5 years 
55 49 37 37 
66 66 66 66 
68 65 65 65 
68 68 68 68 
58 58 58 58 
74 72 72 68 
79 76 76 76 
73 66 58 58 
75 70 64 60 
73 70 70 70 
70 61 61 61 
56 56 
who had postnecrotic or cryptogenic cirrhosis, 
36 patients were positive for HBsAg and the 
remaining 240 were negative for HBsAg 
before transplantation. One- to 5-year sur-
vival rates of B virus carriers were 57%, 48%, 
40%, 40%, and 40%, and those without the 
carrier state were 78%, 77%, 74%, 71 %, and 
71 %. Thus, survival rates of the patients with 
HBsAg were significantly worse than those of 
the patients without HBsAg (Fig 5). 
Recurrence of hepatitis B was examined 
among 24 patients who had had HBsAg-
positive postnecrotic cirrhosis before trans-
plantation and who survived more than 3 
months after transplantation. Five of the 24 
Table 3. Liver Diseases of Pediatric Recipients 
Diseases 
Biliary atresia 
liver-based inborn metabOlic errors 
(Alpha-1-antitrypsin deficiency. Wil-
son's, etc) 
Cirrhosis (postnecrotic and cryptogenic) 
Familial cholestatic syndrome 
Fulminant hepatic failure 
Secondary biliary cirrhosis 
Congenital hepatic fibrosis 
Primary hepatic malignancy 
Budd-Chiari syndrome 
Neonatal hepatitis 
Others· 
No. Patients 
179 
63 
39 
15 
13 
7 
7 
3 
2 
2 
4 
·Primary sclerosing cholangitis, trauma, focal nodular 
hyperplasia, inflammatory pseudotumor. 
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Fig 1. Overall actuarial survival rates of 1,000 
patiants treated with cyclosporine-steroid therapy in 
comparison with overall actual survival rates of 170 
patients treated with azathioprine-steroids therapy. 
patients died between 4 and 15 months, and. 
four of the five died because of recurrent· 
hepatitis B. Eleven of the 24 patients are alive 
between 6 months and 6 years with or after 
recovery from hepatitis B recurrence. Eight of 
the 24 patients are alive without recurrence 
between 4 and 12 months. Only one patient 
has become HBsAg negative after transplan-
tation during a short observation period of 7 
months. This patient had perioperative alpha 
interferon therapy. 
Fifty-three of the 1,000 patients received 
liver transplantation in the presence ()fpri-
mary hepatic malignancy other than bile duct 
carcinoma. Transplantation for 36 of these 53 
patients was primarily to treat advanced he-
patic malignancy that could not be resected by 
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Fig 2. Nearly identical survival rates between 666 
adult recipients and 334 pediatric recipients since 
1980. 
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Fig 3. Survival comparison among adult recipients 
with three most common diseases (postnecrotic cirrho-
sis, primary biliary cirrhosis, and primary sclerosing 
cholangitis) did not show any statistical difference. 
conventional techniques of subtotal hepatec-
tomy. Eighteen of the 36 patients had hepato-
ma, eight had fibrolamellar hepatoma, eight 
had epitheloid hemangioendothelioma, one 
had cholangiosarcoma, and another had 
angiosarcoma. 
For 17 of the 53 patients, liver transplanta-
tion was primarily to treat liver failure, and 
the malignant neoplasm in the diseased liver 
could have been resected by subtotal hepatec-
tomy, if the liver was not terminally diseased. 
Fifteen of these 17 patients had hepatoma, 
one had fibrolamellar hepatom'a and another 
had mixed cholangiohepatoma. 
One- to 5-year survival rates of the 36 
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Fig 4. Survival rates of pediatric recipients with 
liver-based inborn metabolic errors were nearly identi-
cal to those with postnecrotic or cryptogenic cirrhosis. 
Survival rates of children with biliery atresia were 
slightly lower than the other two diseases, but the 
difference was not statistically different. 
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Fig 5. Survival rates of patiants with HBsAg-
positive. postnecrotic cirrhosis were significantly lower 
than those with HBsAg-negative postnecrotic cirrhosis. 
patients who received liver graft for the prin-
cipal indication of malignancy were 65%, 
50%, 29%, 29%, and 29%, respectively (Fig 
6). The survival rates of 18 patients with 
hepatoma were lower than those of eight 
patients with fibrolamellar hepatoma and 
those of eight patients with epitheloid heman-
gioendothelioma (Fig 7). 
Recurrence of primary hepatic malignancy 
after liver transplantation was examined 
among 27 of the 36 patients, who survived 
more than 6 months. Tumor recurrence was 
observed in 13 of the 27 6-month survivors. 
Seven of 11 patients with hepatoma had 
tumor recurrence, and three of which 
occurred within 1 year. Three of seven 
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Fig 6. Survival ratas of patients who received 
transplantation for primary liver malignancy were poor. 
However. survival rates of patients who had transplan-
tation primarily for liver failure and whosa advanced 
cirrhosis contained small malignancies were excellent. 
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Fig 7. Survival rates of patients with hepatoma 
(Heel were significantly lowar than those with fibrola-
mellar hepatoma (FL-Heel and those with epitheloid 
hemangioendothelioma (EHEI. 
patients with fibromellar hepatoma had 
recurrence. All of the recurrences were diag-
nosed more than a year after transplantation. 
Similarly, the two (of eight) patients with 
epitheloid hemangioendothelioma had recur-
rences more than a year after transplantation. 
One patient with cholangiocarcinoma died 
from metastases 31 months after transplanta-
tion, 8 months after tumor recurrence. 
Of the 17 patients who received liver grafts 
primarily for liver failure and whose livers 
harbored hepatic malignancy, only one died 
from recurrence of hepatoma. The remaining 
16 patients are alive, free of tumor between 3 
months to 6 years. The chronic survival of 17 
of 17 patients, with only one late death, is 
noteworthy. 
There were ten recipients who had carci-
noma of the bile duct. In eight patients bile 
duct carcinoma was associated with primary 
sclerosing cholangitis, and in the remaining 
two patients the lesions were the so-called 
Klatskin tumors. One patient with a Klatskin 
tumor died within a month from transplant 
complications, and another died from recur-
rence 8 months after transplantation. Of the 
eight patients who had bile duct carcinoma 
associated with sclerosing cholangitis, one 
died from transplant complications within 1 
month, four patients died from tumor recur-
rence in 4, 12, 14, and 16 months after trans-
502 
plantation, and three patients were alive free 
of tumor in 12, 13, and 14 months. No patient 
with bile duct carcinoma has lived 2 years 
after transplantation in this series. 
There were seven patients who received 
liver transplantation for secondary hepatic 
malignancy. Three of the seven patients died. 
The first patient with carcinoid tumor of the 
small intestine died from transplant complica-
tions within three months, the second patient 
with carcinoid tumor of the small intestine 
and adenocarcinoma of the bile duct died in 6 
months from recurrence of the bile duct can-
cer, and the third patient with adenocarci-
noma of unknown primary site died from 
recurrence 21 months after transplantation. 
The remaining four of the seven patients are 
alive and free of tumor. One patient with 
glucagonoma, which was initially diagnosed 
as a hepatoma with lymphnode metastasis, is 
alive after 21 months, and another patient 
with glucagonoma is alive 10 months after 
transplantation. One patient with gastrinoma 
is alive free of tumor in 2 months. One patient 
with leiomyosarcoma of the small intestine is 
alive, but with recurrent tumor after 15 
months. 
DISCUSSION 
Our first comprehensive report on liver 
transplantation using cyclosporine-steroid 
therapy in 1982 involved only 67 patients (4] 
adults and 26 children), but it had already 
predicted a vast improvement of survival after 
liver transplantation. The article had a strong 
influence upon the practice of hepatology.l 
Five years later, this report, involving 1,000 
patients, confirms the earlier assessment. The 
survival rates of 74% at 1 year and 64% at 5 
years are convincing enough to consider liver 
transplantation as an ultimate therapy for 
various end-stage liver diseases. Unless agents 
that are more effective and safer than cyclo-
sporine are used, further significant improve-
ment of overall survival may not be expected, 
because liver transplantation will be applied 
IWATSUKI ET AL 
for patients of even higher risk than now. 
However, substantial improvements can be 
achieved in some areas. 
The survival rates after liver transplanta-
tion among children under 1 year of age are 
lower than those of older children. One of the 
main reasons for this is technical difficulty 
due to the small structures. The incidence of 
hepatic arterial thrombosis is higher in this 
age group than older age groups. Further 
technical r~finementsI intraoperative use of 
electromagnetic flow-meters, restricted use of 
perioperative coagulation factors a.nd a proper 
anticoagulation therapy will reduce the inci-
dence of technical failures. The lack of small 
sized pediatric organ donor is another reason 
of lower survival rates in this age group. 
Public education to raise awareness of urgent 
need of organ donation must be continued. 
Reduced size liver grafting, such as left lateral 
segment of a larger liver into a small pediatric 
recipient, can be carried out without signifi-
cant additional risk as reported in this forum. 
This approach should decrease the waiting 
period for a proper donor organ, and thus the 
operation can be performed before an infant 
becomes too sick to have a successful trans-
plantation. 
The survival rates of patients older than 60 
years old are also lower than those of younger 
adults. Further experience in selecting elderly 
candidates will establish more accurate crite-
ria of adequate cardiovascular, pulmonary, 
and neurologic functions for liver transplanta-
tion. 
There were no statistical differences in sur-
vival rates among the most common diseases 
in adult recipients (postnecrotic cirrhosis, pri-
mary biliary cirrhosis, and primary sclerosing 
cholangitis) and among those in pediatric 
recipients (biliary atresia, liver-based inborn 
metabolic errors, and postnecrotic cirrhosis). 
However, slightly lower survival rates among 
children with biliary atresia are directly or 
indirectly caused by an unsuccessful portoen-
terostomy and unwise attempts of its revision 
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before transplantation. Although many chil-
dren with extrahepatic biliary atresia have 
been saved by portoenterostomy when it was 
done by proper technique while the liver was 
still relatively normal, there are many other 
unfortunate children whose condition deterio-
rated rather rapidly because of unsuccessful 
attempts of the operation. It is not unusual 
that a child had had several abdominal opera-
tions, such as attempts of portoenterostomy, 
revisions of enterostomy, drainage of abdomi-
nal abscesses, and operations for bowel 
obstruction before transplantation. It is also 
not unusual that children with intrahepatic 
atresia or other nonextrahepatic type of bil-
iary atresia, such as Alagille's syndrome, had 
a portoenterostomy and that children with 
well established cirrhosis and portal hyperten-
sion have received the operation. The portoen-
terostomy should only be performed by 
experienced surgeons at the institutes where 
jaundice-free success rate has been more than 
70%. As liver transplantation has become a 
practical option for children with biliary atre-
sia, indications of portoenterostomy and its 
rare revision must be strictly followed. 
The survival rates of patients with hepatitis 
B surface antigen positive cirrhosis were sig-
nificantly lower than those of patients with 
HBsAg-negative postnecrotic cirrhosis. Re-
currence of viral hepatitis B was a general rule 
despite our efforts at perioperative use of 
anti-hepatitis B immunoglobulin therapy and 
ongoing alpha interferon therapy, The recur-
rence of hepatitis B was the direct or indirect 
cause of death in four of five late deaths 
among the 36 patients. It is worthwhile to note 
that 12 ofthe 36 patients died within 3 months 
from various complications related to trans-
plantation, but not from recurrence of hepati-
tis B. Actually, this high early mortality 
among chronic hepatitis B virus carriers 
influenced the survival rates more signifi-
cantly than the mortality related to recurrent 
hepatitis· B. Immunologic impairment of 
chronic HBsAg carriers could playa signifi-
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cant role in early mortality. Thus, further 
investigations are needed not only for antiviral 
therapy, but also for the means to decrease 
early mortality that was probably not directly 
related to hepatitis B virus. 
Recurrence of hepatic malignancy after 
transplantation resulted in lower survival 
rates of patients who received liver grafts for 
cancer than those of patients without hepatic 
malignancy. However, the mere presence of a 
small, incidental hepatic malignancy in the 
advanced cirrhosis did not influence the sur-
vival rates. When liver transplantation was 
performed to treat a large hepatocellular car-
cinoma that could not be resected by a conven-
tional technique of subtotal hepatectomy, the 
tumor all too frequently recurred within 1 
year. For the last few years, adjuvant chemo-
therapy with adriamycin has been applied for 
these patients as soon as the condition of the 
patients and the graft became stable, usually 1 
or 2 months after transplantation. During this 
small and short exercise, there has been at 
least no significant adverse effects of adjuvant 
chemotherapy. Safer and more effective adju-
vant chemotherapy and/or immunotherapy 
are needed to prevent tumor recurrence. The 
prognosis of fibrolamellar hepatoma and epi-
theloid hemangioendothelioma are better 
than that of hepatoma, as indicated by better 
survival rates, and later and lower incidence of 
recurrence. 
In this series of 1,000 patients, there has 
been no 2-year survivor who had bile duct 
cancer. The recurrence of the tumor within a 
year has been frequent. The facts that bile 
duct cancer was found in eight of 81 patients 
with primary sclerosing cholangitis (10% inci-
dence) and that the survival of these eight 
patients was extremely poor strongly indicate 
the need of earlier transplantation for the 
patients with long standing sclerosing cholan-
gitis. 
In general, metastatic liver tumors consti-
tute a poor indication for liver transplanta-
tion. However, over the years, seven such 
504 
patients had liver replacement accidentally or 
knowingly because of an unusually indolent 
clinical course. The survival rates of these 
highly selected patients were better than gen-
erally expected, particularly if the metastases 
are from pancreatic islet tumors and from 
carcinoid tumors. 
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